Biotech firms continue to attract substantial investment, fueling innovation and growth. Colossal Biosciences raised an additional $120 million in Series C financing to advance de-extinction and avian genetics programs. Synthesize Bio launched with $10 million seed funding to develop AI-driven foundation models for drug discovery based on transcriptomic data. Lōvu Health secured $8 million for its maternal health platform, while Ollin Biosciences emerged from stealth with $100 million intending to challenge leading ophthalmology drugs. These capital infusions reflect sustained investor confidence in biotech innovation across diverse sectors including gene editing, AI, and therapeutic development.